Dr. Philip is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2800 W. Grand Blvd.
Detroit, MI 48202Phone+1 800-436-7936
Summary
- I am a medical oncologist subspecializing in gastrointestinal malignancies and also neuroendocrine tumors. I have a busy clinical practice in an academic setting part of the Karmanos Cancer Center that is an NCI-designated Comprehensive Cancer Center. The hospital is also a stand alone cancer center.
May major clinical and research interests are in pancreatic cancer and also neuroendocrine tumors
Education & Training
- University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 1993 - 1995
- University of LondonPHD, Clinical Pharmacology and Pharmacogenetics, 1982 - 1986
- Guy's Hospital Medical School, University of LondonFellowship, Clinical Research, 1982 - 1986
- University of BaghdadSenior Residency, 1980 - 1981
- Al-Taji HospitalResidency, 1978 - 1980
- University of BaghdadInternship, 1977 - 1978
- University of Baghdad College of MedicineClass of 1977
Certifications & Licensure
- MI State Medical License 1995 - 2026
- KS State Medical License 1995 - 2023
Awards, Honors, & Recognition
- Teaching Award Wayne State University Medical School, 1999, 2004
- Best Doctors of America 2009 - present
- HOUR Detroit Magazine Top Docs 2009, 2010, 2011
- Join now to see all
Clinical Trials
- Bryostatin 1 in Treating Patients With Metastatic Colorectal Cancer Start of enrollment: 1998 Feb 01
- Combination Chemotherapy In Treating Patients With Advanced Cancer Start of enrollment: 1998 May 01
- Combination Chemotherapy in Treating Patients With Stage III or Stage IV Pancreatic Cancer That Cannot Be Removed by Surgery Start of enrollment: 1999 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- 1232 citationsSafety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-05...Charles S. Fuchs, Toshihiko Doi, Raymond Jang, Kei Muro, Taroh Satoh
JAMA Oncology. 2018-05-10 - 325 citationsGemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF.Shadan Ali, Aamir Ahmad, Sanjeev Banerjee, Subhash Padhye, Kristin Dominiak
Cancer Research. 2010-05-01 - 141 citationsDifferentially expressed miRNAs in the plasma may provide a molecular signature for aggressive pancreatic cancer.Shadan Ali, Khaldoun Almhanna, Wei Chen, Philip A. Philip, Fazlul H. Sarkar
American Journal of Translational Research. 2011-01-01
Journal Articles
- A Rapid Method for the Determination of Acetylation Phenotype Using Dapsone.Philip, P.A., Roberts, M.S., Rogers, H.J, British Journal of Clinical Pharmacology. 17:465-69, 1984
- Genetically Determined Debrisoquine Oxidation Capacity in Bladder Cancer.Cartwright, R.A, Philip, P.A., Rogers H.J., Glashan, R.W, Carcinogenesis. 5: 1191-92, 1984
- Influence of Age, Sex and Body Weight on the Dapsone Acetylation Phenotype.Philip, P.A., Gayed, S.L., Roger, H.J., Crome, P, British Journal of Pharmacology. 23:709-713, 1987
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- Molecular Aspects of Breast Carcinoma.Philip, P.A., Harris, A.L, Current Medical Literature. pp 3-7, 1992, Royal Society of Medicine
- The influence of a continuous infusion of hydroxyurea (HU) on the uptake of 5-iodo-2-deoxyuridine (IUdR) by bone marrow and tumor cells in man.Philip P.A., Kaklamanis L., Morrison H., Gatter K.C., Carmichael J., Harris A.L, British Association of Cancer Research meeting, Manchester, England
- The effect of ifosfamide on antipyrine clearance in patients with non-small cell lung cancer.Lind M., Philip P.A., Margison J., et al, Proceedings of AACR, 32
- Join now to see all
Lectures
- Phase II Study of Gemzar and Cisplatin in Advanced or Metastatic Pancreatic Cancer.Seminar, U.S. Gemzar Investigator’s Meeting, Memphis, TN
- Phase II Study of Carboplatin and Paclitaxel in Gastric and Esophageal Cancer.Seminar, Fox Chase and Free University Symposium, St. Thomas, Virgin Islands
- Protein Kinase C Modulators in Cancer Therapy: Bryostatin 1.Iowa Oncology Society Annual Meeting, Des Moines
- Join now to see all
Other
- Current Strategies in Previously Untreated Patients with Advanced Colorectal Cancer.Philip PA, Physicians Education Resource, 7(3): 3-6, 2003
- Experience with Docetaxel in the Treatment of Gastric Cancer.Philip PA, Seminars in Oncology. 32(suppl 4): S24-S38
- Liver Directed Therapies in Hepatocellular Cancer.Choi M and Philip PA, Community Oncology
- Join now to see all
Press Mentions
- Cornerstone Pharmaceuticals to Present Pancreatic Cancer, Clear Cell Sarcoma and Biliary Tract Cancer Research Featuring CPI-613® (Devimistat) at the 2022 American Society of Clinical Oncology (ASCO) Annual MeetingJune 1st, 2022
- Karmanos Cancer Institute Recognized Its 2019 Heroes of CancerNovember 19th, 2019
- Rafael Pharmaceuticals’ AVENGER 500 Clinical Trial MilestoneOctober 10th, 2019
- Join now to see all
Grant Support
- Protocol Review And Monitoring SystemNational Cancer Institute2011–2012
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: